drugset / Trial / NCT06510010
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oesophagogastric junction. It evaluates the perioperative oxaliplatin with S-1 (SOX) combined H. pylori eradication versus oxaliplatin with S-1 in the management of H. pylori-positive locally advanced adenocarcinoma of the gastric and oesophagogastric junction (cT3/4a Nx or T2 N2/3, M0) , assessing their values and advantages.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2026-12-28
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Omeprazole | Other / unclassified | 20 mg | — |
| Subject | bismuth subcitrate | Unknown | 220 mg | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg/m2 | Oral |